TOP-5 Price Targets of Analysts on 26.11.25
Reading Time: 3 minutes
Janux Therapeutics [US47103J1051] H.C. Wainwright reaffirms Buy rating with a price target of 70 USD (105% upside potential) At the center is the leading candidate JANX007, which shows promising results in a Phase 1 study for the treatment of metastatic castration-resistant prostate cancer. Notably, it has a favorable safety profile with predominantly low-grade cytokine release syndrome, representing a significant advantage over comparable T-cell engager therapies. An objective overall response rate of 50% as well as a significant reduction in...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
